Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer

PURPOSE: Adding antiangiogenic therapy to standard chemotherapy has improved response rates and progression-free survival in metastatic breast cancer (BC) patients. This phase II study evaluated cardiac safety of bevacizumab with/without trastuzumab with two docetaxel-based regimens in early BC. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurvitz, Sara A, Bosserman, Linda D, Chan, David, Hagenstad, Christopher T, Kass, Frederick C, Smith, Frederick P, Rodriguez, Gladys I, Childs, Barrett H, Slamon, Dennis J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031367/
https://www.ncbi.nlm.nih.gov/pubmed/24860718
http://dx.doi.org/10.1186/2193-1801-3-244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031367/
https://www.ncbi.nlm.nih.gov/pubmed/24860718
http://dx.doi.org/10.1186/2193-1801-3-244

Ejemplares similares